- Home
- PSNL vs ONCY Comparison
PSNL vs ONCY Comparison
Compare PSNL & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- ONCY
- Stock Information
- Founded
- PSNL 2011
- ONCY 1998
- Country
- PSNL United States
- ONCY Canada
- Employees
- PSNL N/A
- ONCY N/A
- Industry
- PSNL Medical Specialities
- ONCY Pharmaceuticals and Biotechnology
- Sector
- PSNL Health Care
- ONCY Health Care
- Exchange
- PSNL Nasdaq
- ONCY Nasdaq
- Market Cap
- PSNL 580.3M
- ONCY 49.1M
- IPO Year
- PSNL 2019
- ONCY 1999
- Fundamental
- Price
- PSNL $6.37
- ONCY $1.17
- Analyst Decision
- PSNL Strong Buy
- ONCY Strong Buy
- Analyst Count
- PSNL 5
- ONCY 4
- Target Price
- PSNL $8.00
- ONCY $4.33
- AVG Volume (30 Days)
- PSNL 1.9M
- ONCY 1.6M
- Earning Date
- PSNL 08-06-2025
- ONCY 07-31-2025
- Dividend Yield
- PSNL N/A
- ONCY N/A
- EPS Growth
- PSNL N/A
- ONCY N/A
- EPS
- PSNL N/A
- ONCY N/A
- Revenue
- PSNL $85,694,000.00
- ONCY N/A
- Revenue This Year
- PSNL $0.45
- ONCY N/A
- Revenue Next Year
- PSNL $25.75
- ONCY N/A
- P/E Ratio
- PSNL N/A
- ONCY N/A
- Revenue Growth
- PSNL 15.57
- ONCY N/A
- 52 Week Low
- PSNL $1.52
- ONCY $0.33
- 52 Week High
- PSNL $7.79
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- PSNL 51.74
- ONCY 75.27
- Support Level
- PSNL $6.52
- ONCY $0.71
- Resistance Level
- PSNL $7.32
- ONCY $1.31
- Average True Range (ATR)
- PSNL 0.52
- ONCY 0.12
- MACD
- PSNL -0.06
- ONCY 0.04
- Stochastic Oscillator
- PSNL 25.85
- ONCY 81.33
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.